Participate in Research

Browse Clinical Trials
Esophageal Cancer Study
Protocol: SITE00000112
Full Title
A PHASE III, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Description
This study enrolls adults with esophageal cancer. The purpose of this study is to compare the effects of different combinations of medications to treat this cancer. Atezolizumab and tiragolumab are experimental drugs, which means the U.S. Food and Drug Administration (FDA) has not approved them, alone or in combination, for the treatment of esophageal cancer.

In this study, you will get either atezolizumab plus tiragolumab, atezolizumab plus placebo, or double placebo. A placebo looks like a drug but has no active ingredient. You will take them for about 1 year and be in the study for up to 2 years. You will have study visits to our office every 21 days for 12 months. We will ask you questions about your health throughout the study. Compensation is not available but reasonable travel costs may be reimbursed. Study takes place at Kaleida Health facilities.
Compensation: No
Eligibility
Adults ages 18+.
Diagnosed with esophageal cancer (squamous cell carcinoma of the esophagus) in stage II-IIVA.
The cancer is unresectable, which means you are unable to unwilling to have surgery.
You have received chemoradiotherapy and your disease did not worsen.
Age Group: Adults
Principal Investigator: ROBERTO PILI
Contact(s)
Ashlee Lang
alang@kaleidahealth.org
+1 716-859-8519
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions
Study Team Login